Company ProfilePremium

Jacobson Pharma Corporation Limited

Company Profile Analysis

Ticker: 2633.HK雅各臣科研製藥有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Jacobson Pharma Corporation Limited - Company showcase

Year Founded & Workforce

1,768 Employees

Jacobson Pharma Corporation Limited logo

Jacobson Pharma Corporation Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Jacobson Pharma Corporation Limited Overview

Jacobson Pharma is Hong Kong's largest locally based, vertically integrated generic-drug manufacturer. It runs nine licensed pharmaceutical production facilities in Hong Kong, an SAP-driven central warehouse and its own truck fleet, regulatory, quality and sales operations. Around 97% of revenue comes from Hong Kong, and roughly half from one major customer, almost certainly the Hospital Authority, which runs the public hospital system. Since spinning off and then fully distributing its branded consumer-health arm (JBM Healthcare) in 2021–2023, it has become a focused "essential medicines and specialty drugs" company. Its growth levers are a 241-product generics pipeline, an aggressive in-licensing programme (46 deals in FY2026), biosimilars, and a niche position as one of only two licensed CAR-T handlers in Hong Kong. Earnings quality is high: 43% gross margin, 34.5% adjusted EBITDA margin, and HK$301.6m attributable profit in FY2026. The equity trades at about 6.4x trailing earnings, with a founder who controls about 70% of the shares.


Company's own description (AR FY2026, paraphrased)

The company calls itself a leading Hong Kong pharmaceutical company that is vertically integrated across research, development, production, sale and distribution of essential medicines and specialty drugs. It says it is a major provider of generic drugs in Hong Kong, with one of the widest sales and distribution reaches into both the Public Sector (Hospital Authority and Department of Health) and the Private Sector (private hospitals, clinics, doctors in private practice and registered pharmacies). It is also expanding into selected Asian markets. It runs 9 licensed production facilities in Hong Kong and manages its own warehousing, logistics, regulatory, quality control, and sales and marketing functions. Its stated vision is to become a leading player in essential medicines, specialty drugs and healthcare solutions in Greater China and Asia.

The AR FY2026 lists four competitive strengths:

  1. Leadership across a wide range of essential and specialty drugs in Hong Kong, including respiratory, cardiovascular, central nervous system (CNS), gastrointestinal and oral anti-diabetic medicines, with a strategic tilt toward specialty drugs and biosimilars.

  2. R&D capability that the company says leads Hong Kong generic manufacturers by number of new drug registrations in recent years, plus partnerships with local and overseas research institutions.

  3. Sales and distribution covering substantially all Public and Private Sector institutions and registered pharmacies.

  4. Logistics infrastructure that includes a central distribution centre, a high-capacity truck fleet, and specialised vaccine and Advanced Therapy Product (ATP) cold-chain capability.

Business model and revenue model

Revenue streamNatureDisclosure status
Manufactured generic drugs (own registrations)Product sales to the Public Sector (mostly via tenders and contracts) and the Private SectorNot split out; the bulk of revenue
In-licensed specialty drugs, biologics, biosimilars and vaccinesProduct sales of partner products under exclusive HK/Macau licencesNot split out
Logistics, supply-chain and patient-support services (e.g., Yikaida CAR-T)Service fees for ATP cold-chain, logistics, sales and marketing supportNot split out; believed small
e-Jacob Pharma2U digital orderingChannel for product sales to 1,200+ clinicsNot a separate revenue line
Rental and licence income (e.g., licence of Tai Po factory space to JBM's Europharm HK)Other incomeHK$247,000 a month under the Oct 2025 agreement
Licensing out / royalties——
Subscription——

Product sales make up essentially all revenue. The group reports one operating segment ("essential medicines and specialty drugs"), so the product/service/licensing mix is not publicly disclosed in numbers.

Value-chain position

Jacobson covers the full value chain for off-patent medicines in Hong Kong: formulation and pre-formulation R&D, stability studies and dossier registration with the Pharmacy and Poisons Board, PIC/S-GMP manufacturing across solid, semi-solid, liquid and sterile (eye drops and injections) dosage forms, warehousing, logistics and direct field sales. For in-licensed innovative and specialty medicines it acts as local marketing authorisation holder, importer, distributor and patient-services provider. Raw materials (active pharmaceutical ingredients and excipients) are bought from approved vendors. Material costs were 41% of cost of sales in FY2026.

Customer types and concentration

Public Sector: One customer accounted for more than 10% of revenue: HK$800.8m in FY2026 (≈51.0% of revenue), up from HK$757.2m in FY2025 (≈48.0%). The customer is not named, but given Hong Kong's market structure it is almost certainly the Hospital Authority (inference).

Private Sector: Private hospitals, general practitioners, specialists, dentists, veterinarians (through e-Jacob Pharma2U) and registered pharmacies.

Regional customers: Macau (HK$31.6m), Chinese Mainland (HK$23.3m) and other markets (HK$0.2m) in FY2026.

End markets served

Hong Kong prescription pharmaceuticals (public and private), the Macau pharmaceutical market, limited Mainland China sales (cold and flu and gastrointestinal lines), Greater Bay Area designated hospitals (Arsenic Trioxide Oral Solution approved for GBA use in 2022), and a new veterinary diagnostics niche (an in-licensed DNA test for animal cancer treatment options, FY2026).

Independent characterisation

Jacobson is best seen as a Hong Kong-centric, quasi-utility supplier of essential generics to a single-payer public system, with an expanding specialty in-licensing "platform" on top. Its economics rest on registration barriers (Hong Kong's small market discourages multinational generic makers from registering low-value molecules), tender scale and local manufacturing credibility. The 2023 removal of the consumer-brands business (JBM) made the earnings stream lower in growth but more defensive and higher in margin. The main strategic questions are (i) how dependent it is on Hospital Authority tender pricing, (ii) whether in-licensed specialty and biosimilar products can offset seasonal volatility in cold and flu demand, and (iii) whether the HK$600m+ Tai Po smart-factory capex will earn its cost of capital.

Strategy

Stated strategy (AR FY2026, paraphrased)

Vision: To be a leading player in essential medicines, specialty drugs and healthcare solutions in Greater China and Asia.

Mission: Create sustainable value through accessible, cost-effective products that improve patient outcomes. Enrich communities through responsible and inclusive practices. Build shareholder value.

Culture: "Challenge, Connect, Commit", operating as "one company, one team".

Three strategic pillars: (Chairman's Statement): portfolio expansion, innovation, manufacturing excellence.

Growth engines: cited by management: the chronic disease and specialty medicines portfolio, in-licensed products, biosimilars and biologics, advanced therapies (CAR-T), digital procurement, and Hong Kong primary-care reform.

Annual report theme for FY2026: "Steadfast Commitment to Growth Strategies and Execution Excellence."

Strategic initiatives in the last 24 months

InitiativeStartDescription and statusTargets / metricsSource
Tai Po InnoPark smart factoryFeb 2025Ten AI- and robotics-enabled production lines (sterile eye drops, solid dosage, oral liquids). Supported by the HK Government's New Industrialisation Acceleration Scheme. Main contractor works contract HK$607.2m (1 Apr 2026).First line trial H1 2027; full operation H1 2029AR FY2026; HKEX
In-licensing programmeOngoing20 exclusive in-licences in FY2025; 46 in FY2026 (specialty drugs, biologics, vaccines, advanced therapies)No numeric targetAR FY2025; AR FY2026
Biosimilars and biologics pushFY2026Prefilled syringe and pen formats—AR FY2026
CAR-T and ATP logistics (Yikaida)Feb 2025End-to-end supply chain in HK and Macau with Fosun Pharma and Fosun Kairos4 patients treated by Mar 2026AR FY2026
e-Jacob Pharma2UOngoingDigital B2B ordering; new features, analytics, loyalty schemesOver 1,200 clinicsAR FY2026
R&D pipeline expansionOngoingPipeline 219 (Mar 2025) → 241 (Mar 2026); 23 approvals in FY2026—AR FY2025; AR FY2026
Veterinary entryFY2026In-licensed DNA test for animal cancer treatment options—AR FY2026
Fotan facility revampFY2025–26Revamped facilities; oral solid dosage operations started at a subsidiaryOral liquid output +65.5%; semi-solid output ×4.7AR FY2026
Community Pharmacy Programme / Community Drug Formulary participationFY2027Positioning for the government's CPP, phased in from Q4 2026—AR FY2026
Greater Bay AreaOngoingGBA designated-hospital access (Arsenic Trioxide Oral Solution); regional integration—AR FY2026; FY2023 interim
ESG "5 to Thrive"Since FY2023Five pillars aligned with UN SDGs: Corporate Governance, Product Responsibility, Societal Engagement, Environmental Stewardship, Employee CommitmentReduction targets set for GHG, waste, energy and water; numbers in the ESG report, not capturedAR FY2026
Clinical-stage asset2,026The FY2025 results release mentioned a global Phase III trial to start in 2026, targeting market approval in 2028. The product was not identified in the extract reviewed, and AR FY2026 did not repeat it.Approval target 2028FY2025 results release (Quamnet)
Cost disciplineFY2026Process optimisation and cost control credited for protecting profitNot quantifiedAR FY2026

Medium-term financial targets and guidance

No quantitative guidance has been published. Management gives no revenue, margin, EPS or capex targets. Qualitative outlook (AR FY2026): optimism based on ageing demographics, chronic disease prevalence, primary-care reform (District Health Centres, CDCC Pilot Scheme, CDF, CPP from Q4 2026), patent expiries, a faster new-drug evaluation mechanism (phased in from March 2026), and GBA integration. The dividend policy aims for "reasonably stable and consistent" dividends, normally paid twice a year, while keeping reserves for M&A.

Products & Services

The company does not publish SKU-level revenue. The catalogue below is built from AR FY2026, AR FY2025 and interim disclosures. Pricing is set through Hospital Authority tenders and private-market negotiation; product-level prices are not publicly disclosed.

Own-manufactured generics by therapeutic area

Therapeutic areaNamed products / descriptionTarget customerRecent activitySource
Cardiovascular – antihypertensivesOlmesartan tablets (launched H1 FY2023); combination antihypertensives addedPublic and Private Sectors, chronic-care clinicsCalled a key growth driver in FY2026FY2023 interim; AR FY2026
Cardiovascular – lipid-loweringAtorvastatin tablets (launched H1 FY2023)Private clinics; Public tendersStrong private-market demand in FY2026FY2023 interim; AR FY2026
Cardiovascular – anticoagulantsInnovative anticoagulants added through in-licensingHospitalsAdded in FY2026AR FY2026
Central nervous systemAnxiolytics, hypnotics, ADHD medications, neuropathic pain productsPsychiatric services, private practiceNew public tenders won for neuropathic pain in FY2026AR FY2026
Oncology and supportive careArsenic Trioxide Oral Solution (oral APL therapy; first HK-made specialty drug approved for GBA designated hospitals); expanded chemotherapy rangeHA oncology units; GBA hospitalsContinued strong performance; oncology tender wins in FY2026AR FY2026; FY2023 interim
Respiratory / cold and flu / coughCold and flu and cough suppressant preparations, including paediatric formulationsPublic and Private Sectors; MainlandSales fell in FY2026 as the flu season normalisedAR FY2026
GastrointestinalGI product rangePublic and private; MainlandMainland GI demand fell in FY2026AR FY2026
Oral anti-diabeticsDiabetes therapiesChronic-care settingsSupported by CDCC scheme demandAR FY2026
Ophthalmology (sterile)Eye drops (PIC/S GMP sterile line); 10 future Tai Po lines include sterile eye dropsHospitals and clinicsEye-drop output +7.8% YoY in FY2026AR FY2026
Dermatology / topicalSemi-solid formulationsClinics and pharmaciesSemi-solid output up about 4.7-fold in FY2026AR FY2026
Oral liquidsOral solutions, including specialty leukaemia oral liquids developed with a medical schoolHospitalsOral-liquid output at one subsidiary +65.5% in FY2026AR FY2026
Sterile injectablesInjection line (PIC/S GMP)Hospitals—FY2022 AR

In-licensed specialty products, biologics, biosimilars and vaccines

CategoryDescriptionCount / timingSource
Specialty drugs (exclusive in-licences)Oncology, rheumatology, haematology, gastroenterology, cardiology, rare diseases20 agreements in FY2025AR FY2025
Specialty drugs, biologics, vaccines, advanced therapiesImmunology, rheumatology, oncology, haematology, cardiology, neurology, infectious disease, supportive care46 agreements in FY2026AR FY2026
Biosimilars and biologicsPre-filled syringe and pre-filled pen formats to improve adherenceExpanding in FY2026; individual molecules not disclosedAR FY2026
Influenza vaccinesA full range of influenza vaccines addedFY2026AR FY2026
Veterinary diagnosticsIn-licensed DNA testing service to guide treatment options for animal cancer; described as an entry point into animal healthFY2026AR FY2026

Licensors are described only as "leading global pharmaceutical partners". Individual counterparties and molecules are not publicly disclosed.

Services and platforms

OfferingDescriptionCustomers / metricsLaunchSource
Yikaida (axicabtagene ciloleucel) supply-chain and patient careEnd-to-end ATP cold chain, logistics, sales and marketing support for Fosun Kairos's CAR-T therapy for relapsed or refractory DLBCL in Hong Kong and Macau. Avoids shipping patient material abroad.3 HK and 1 Macau patients through apheresis and reinfusion by Mar 202620 Feb 2025 (HK); Macau debut in FY2026AR FY2025; AR FY2026
ATP logistics licenceLicensed Advanced Therapeutic Product handler; one of two authorised CAR-T handlers in Hong Kong—By FY2025AR FY2026
Vaccine logisticsSpecialised cold-chain storage and distribution——AR FY2026
e-Jacob Pharma2UProprietary mobile and web e-ordering platform for healthcare professionals. Features include delivery label requests, offer selection, reward programmes and data analytics.Over 1,200 registered clinics (GPs, specialists, dentists, vets)Not disclosed; expanded in FY2026AR FY2026
Contract warehousing / logisticsSAP-powered central warehouse, truck fleet——AR FY2026

Pipeline (31 March 2026)

StageNumber of products
Registration approval obtained (within pipeline)79
Submitted, pending approval10
Development done; in stability preparation or study67
Formulation / pre-formulation25
Total pipeline241
New approvals received in FY202623
Entered stability testing in FY202619
Added to pipeline in FY202622

The stage counts sum to 181, not 241. The company does not reconcile the difference, which may be products at other stages or a different counting basis. AR FY2025 showed a similar gap (219 total vs 163 summed). Products pending approval cover CNS, cardiovascular, GI, anti-infective, pain and dermatology.

Divested consumer brands (for reference; now owned by JBM Healthcare)

Po Chai Pills, Ho Chai Kung Tji Thung San (acquired Dec 2016 for HK$568m), Tong Tai Chung Woodlok Oil, Flying Eagle Wood Lok Medicated Oil, Contractubex Scar Gel, Doan's Ointment, Saplingtan, Shiling Oil, Col-gan Tablet, and the Hong Ning Hong OTC distribution business (Mar 2017 press release). These left the group on 24 Aug 2023. Jacobson still has commercial dealings with JBM through continuing connected transactions (renewed 6 Mar 2026) and the Tai Po factory licence.

Financial Narrative

Basis warning: FY2022 and FY2023 are as originally reported, including Branded Healthcare. FY2024 is continuing operations, except that attributable profit and EPS include discontinued operations. FY2025 and FY2026 are wholly continuing. A restated FY2023 continuing figure is shown where available.

Income statement

Sources: FY2022 AR; FY2023 results announcement; FY2024 results announcement; AR FY2025; FY2026 results announcement. FY2023 cost of sales is computed as revenue minus gross profit. FY2024 profit for the year of HK$290.8m includes HK$52.4m from discontinued operations and a HK$28.2m distribution gain. Continuing profit was HK$210.2m and continuing EPS was 10.95 HK cents. The FY2024 special DPS is the in-specie JBM distribution valued at HK$1.16 per JBM share. StockAnalysis (S&P Global) shows somewhat different operating income (FY2025 HK$432.9m, FY2024 HK$311.4m) and EBITDA (FY2026 HK$506.5m) because it classifies items differently.

FY2026 income statement detail (HK$ m)

Margins and growth

Revenue CAGR (computed): On the continuing generic basis, FY2023 (restated HK$1,267.6m) to FY2026 (HK$1,569.5m) is a 3-year CAGR of about 7.4%. FY2022 to FY2026 on the generic segment basis (HK$1,191.3m to HK$1,569.5m) is a 4-year CAGR of about 7.1%. As reported, including the divested business, revenue shrank from HK$1,595.5m to HK$1,569.5m (−0.4% CAGR). This reflects the deconsolidation, not organic decline.

Commentary. The FY2022 to FY2025 period was a margin up-cycle. Gross margin rose about 500bp (38.9% to 43.9%) as the mix shifted toward chronic and specialty products, manufacturing utilisation improved, and the lower-margin consumer business left. Adjusted EBITDA margin peaked at 36.3% in FY2025, helped by an unusually long 2024/25 Hong Kong influenza season. FY2026 marks an inflection to flat growth. Revenue fell 0.5% and adjusted EBITDA fell 5.4% as cold and flu demand normalised, staff costs rose (+4.8% in cost of sales), and depreciation went up for the revamped Fotan facilities. Attributable profit still rose slightly (+0.3%) thanks to a HK$10.7m drop in finance costs, a HK$11.8m lower tax charge, and higher associate income. That makes FY2026 profit quality somewhat lower than the headline suggests: profit from operations fell 6.2%. Note also that FY2023 profit included a one-off HK$34.2m Employment Support Scheme subsidy.

Balance sheet

Sources: FY2022 AR; FY2023 results; FY2024 results; FY2026 results announcement (balance sheet). FY2023 total liabilities are computed as total assets minus equity. Goodwill is not separately disclosed in the extracts reviewed; intangible assets include capitalised development costs and software. No assets were pledged against bank loans at 31 March 2025 or 2026. All bank loans are in HK$.

Commentary. The balance sheet shrank by about HK$1.9bn between FY2023 and FY2024 because JBM was distributed. Net gearing then fell to a low of 8.3% in FY2025. FY2026 marks a re-leveraging inflection: bank loans rose HK$143.8m (+20.1%) to fund the Fotan revamp and the Tai Po project. Meanwhile cash fell HK$139.2m after HK$230.0m of dividends paid, including the FY2025 special dividend. Net gearing rose to 20.8%. Short-term debt also became much more prominent (current bank loans HK$478.0m vs HK$237.2m), which cut net current assets by 45% to HK$268.7m. Refinancing is not a concern given relationship banking with HSBC, Standard Chartered and Chong Hing, but the maturity profile has clearly shortened. Inventory rose 11.8% for safety stocks at the revamped facilities and for new launches.

Impairment headroom (watch item): The recoverable amount of cash-generating units exceeded carrying amount by HK$825.8m at 31 March 2026. That compares with HK$1,268.3m at 31 March 2025 and HK$1,157.3m (generic CGUs) at 31 March 2024. Management still considers impairment unlikely under reasonably possible changes.

Cash flow

The cash flow statement is in AR FY2026 (page 60), but operating cash flow and free cash flow were not captured in the sources reviewed. They are therefore left blank rather than estimated. No share buybacks were identified in the period. Management describes FY2026 operating cash generation as stable and strong. The FY2024 distribution in specie (fair value HK$564.6m) was non-cash.

Ratios

Commentary. Returns have improved structurally since the JBM separation. ROE moved from single digits to about 12.5%, and ROA more than doubled, because the remaining business is more capital-efficient than the consolidated group was. The long cash conversion cycle (about 172 days, driven by about 150 inventory days) is typical of a multi-SKU generic maker that holds safety stock for public-sector supply obligations. It lengthened in FY2026. Interest coverage is comfortable at 12.7x because Hong Kong rates fell. Net debt to EBITDA of about 0.9x leaves room to fund the HK$607.2m Tai Po contract, but leverage will likely rise further before the plant generates revenue from FY2028 onward.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

SegmentFY2022FY2023FY2024FY2025FY2026

Generic Drugs / Essential Medicines & Specialty Drugs (HKD Mn)

1,191.31,267.61,467.81,576.91,569.5

Branded Healthcare, consolidated (HKD Mn)

404.2518.0———

Total revenue as reported at the time (HKD Mn)

1,595.51,785.61,467.81,576.91,569.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2022FY2023FY2024FY2025FY2026

Generic segment YoY revenue growth (%)

13.66.415.87.4-0.5

Branded Healthcare YoY revenue growth (%)

1.828.2———

Generic share of reported revenue (%)

74.771.0100100100

Branded Healthcare share of reported revenue (%)

25.329.0———

Results by Segment and Segment Margins & Growth (%)

Metric (HKD Mn)FY2023FY2024FY2025FY2026

Adjusted EBITDA – Generic / continuing (HKD Mn)

444.2453.1572.8541.6

Adjusted EBITDA – Branded Healthcare (HKD Mn)

124.382.7——

Adjusted EBITDA margin – Generic / continuing (%)

35.030.936.334.5

Profit before tax – continuing (HKD Mn)

—254.6373.6362.6

PBT margin – continuing (%)

—17.323.723.1

Group Entities

EntityRoleSource

Jacobson Pharma Corporation Limited (Cayman)

Listed holding company

AR FY2026

Jean-Marie Pharmacal Co. Ltd (HK)

Manufacturing; sponsor of the Tai Po InnoPark smart-factory project

AR FY2026; FY2022 AR

Ching Mei Drug Company (HK)

Indirect wholly owned subsidiary named as owner of the Tai Po site in the 1 Apr 2026 tender announcement. "Ching Mei" (精美) looks like the Chinese-name transliteration of Jean-Marie, so this is probably the same entity; not confirmed.

HKEX 1 Apr 2026 (via iTiger)

Europharm Laboratoires Co. Ltd (HK)

Manufacturing (oral solids); Tai Po InnoPark factory; counterparty in Li Chung Shing Tong share purchases

FY2022 AR; HKEX Nov 2024, Oct 2025

Medipharma Ltd / Cawah Holdings Ltd

Generic manufacturer acquired in 2016

ACN Newswire 2016

American Unicorn Laboratories

Manufacturer, 100% owned since FY2021

FY2022 AR

—

ATP-licensed logistics; one of two authorised CAR-T handlers in Hong Kong

AR FY2026

—

Has an employee union under PRC labour law

AR FY2026

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (HKD Mn)

1,595.51,785.61,467.81,576.91,569.5

Revenue, continuing-ops basis (HKD Mn)

1,191.31,267.61,467.81,576.91,569.5

Cost of sales (HKD Mn)

975.01,038.4847.3884.0891.6

Gross profit (HKD Mn)

620.5747.2620.5692.9677.9

Profit from operations (HKD Mn)

260.9410.8333.1414.6388.7

Adjusted EBITDA (HKD Mn)

441.6568.2453.1572.8541.6

Finance costs (HKD Mn)

25.767.478.741.430.7

Profit before tax (HKD Mn)

231.4339.8254.6373.6362.6

Income tax (HKD Mn)

——44.472.861.0

Profit for the year (HKD Mn)

187.7283.2290.8300.8301.6

Profit attributable to shareholders (HKD Mn)

177.7251.0267.0300.8301.6

EPS basic (HK cents)

9.2713.1313.9015.1515.10

EPS diluted (HK cents)

9.2713.1313.9015.1515.10

Ordinary DPS (HK cents)

3.885.185.509.009.00

Special DPS (HK cents)

0029.526.000

Total DPS incl. special (HK cents)

3.885.1835.0215.009.00

Business Lines

LineFY2025FY2026

Other net income (HKD Mn)

45.935.5

Selling and distribution expenses (HKD Mn)

124.0127.3

Administrative and other operating expenses (HKD Mn)

200.3197.5

Share of profits of associates (HKD Mn)

0.44.7

Depreciation (HKD Mn)

125.2135.7

Amortisation of intangibles (HKD Mn)

18.718.1

Cost of sales – materials (HKD Mn)

382.7365.5

Cost of sales – staff (HKD Mn)

297.9312.2

Cost of sales – other production (HKD Mn)

203.4213.9

Effective tax rate (%) (computed)

19.516.8

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

38.941.842.343.943.2

Operating margin, profit from ops / revenue (%) (computed)

16.423.022.726.324.8

Adjusted EBITDA margin (%)

27.731.830.936.334.5

Attributable net margin (%)

11.114.118.219.119.2

Revenue growth, as reported (%)

10.311.9-17.87.4-0.5

Revenue growth, continuing basis (%)

13.66.415.87.4-0.5

Balance Sheet and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (HKD Mn)

4,755.55,380.53,486.93,645.23,563.9

Total liabilities (HKD Mn)

1,797.62,124.01,090.51,167.71,223.7

Total equity (HKD Mn)

2,958.03,256.52,396.42,477.42,340.2

Equity attributable to shareholders (HKD Mn)

———2,453.22,316.0

Cash and cash equivalents (HKD Mn)

478.71,036.4411.9509.0369.9

Bank loans – current (HKD Mn)

——112.8237.2478.0

Bank loans – non-current (HKD Mn)

——592.2476.5379.5

Total bank loans (HKD Mn)

1,341.61,543.7705.0713.7857.5

Lease liabilities (HKD Mn)

———59.553.4

Net debt, bank loans less cash (HKD Mn)

862.9507.3293.1204.7487.6

Net gearing (%)

29.215.612.28.320.8

Intangible assets incl. goodwill (HKD Mn)

——435.8421.1427.2

Property, plant and equipment (HKD Mn)

———1,494.11,508.5

Investment properties (HKD Mn)

———163.9156.1

Other financial assets (HKD Mn)

———398.6349.0

Interests in associates (HKD Mn)

———50.869.9

Inventories (HKD Mn)

314.6368.0317.9332.9372.2

Trade and other receivables (HKD Mn)

——233.4194.4230.9

Trade and other payables and contract liabilities (HKD Mn)

——216.5258.7183.8

Current assets (HKD Mn)

———1,038.0986.1

Current liabilities (HKD Mn)

———553.1717.4

Net current assets / working capital (HKD Mn)

———484.8268.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Dividends & Capital Returns

MetricFY2025FY2026

Additions to PP&E and investment properties (HKD Mn)

—149.6

Capitalised development costs and software (HKD Mn)

—24.2

Dividends paid in cash (HKD Mn)

59.6230.0

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE, company-reported (%)

——10.312.312.5

ROE, profit / average equity (%) (computed)

6.59.1———

ROA, attributable profit / year-end assets (%) (computed)

3.74.77.78.38.5

ROIC, after-tax op. profit / (equity + debt + leases − cash) (%) (computed)

———12.211.2

Current ratio (x) (computed)

———1.881.37

Debt / equity, bank loans (x) (computed)

0.450.470.290.290.37

Net debt / adjusted EBITDA (x) (computed)

1.950.890.650.360.90

Interest coverage, op. profit / finance costs (x) (computed)

10.26.14.210.012.7

Asset turnover, revenue / year-end assets (x) (computed)

0.340.330.420.430.44

Inventory days on COGS (computed)

——137137152

Trade receivable days (computed)

———3441

Trade payable days on COGS (computed)

——221721

Cash conversion cycle, days (computed)

———154172

Dividend payout, ordinary + special / attributable profit (%) (computed)

41.839.5—99.759.7

Revenue by Region

RegionFY2022FY2023FY2024FY2025FY2026

Hong Kong (HKD Mn)

1,428.41,552.31,421.41,514.61,514.3

Chinese Mainland (HKD Mn)

80.0156.333.434.623.3

Macau (HKD Mn)

59.648.112.927.631.6

Others (HKD Mn)

27.528.90.10.10.2

Total (HKD Mn)

1,595.51,785.61,467.81,576.91,569.5

Geographic Revenue

RegionFY2025 growth (%)FY2026 growth (%)FY2026 share (%)

Hong Kong

6.60.096.5

Chinese Mainland

3.6-32.71.5

Macau

114.014.52.0

Others

0.0102.00.0

Valuation Snapshot

MetricValueSource

Last price (9–10 Oct 2026)

HK$0.97

Stockopedia; Simply Wall St

52-week range

HK$0.94 – HK$1.51

Simply Wall St

1-year total shareholder return

−33.1%

Simply Wall St

3-year total shareholder return

+49.2%

Simply Wall St

5-year total shareholder return

+61.7% (includes the JBM distribution in specie)

Simply Wall St

12-month relative strength

−56.3%

Stockopedia

Capital Markets Data (HKD)

MetricJul 2025Aug 2025Sep 2025Oct 2025Nov 2025Dec 2025Jan 2026Feb 2026Mar 2026Apr 2026May 2026Jun 2026

Monthly high (HKD)

1.7801.6191.5301.5101.4901.3301.3101.2801.2801.2501.2301.150

Monthly low (HKD)

1.6001.4201.4001.4401.3401.2201.2301.2301.1901.1101.1200.980

Valuation Multiples

MultipleJacobsonNote

Market cap

HK$1,940m

2,000.2m shares

Enterprise value

≈HK$2,481m

  • bank loans 857.5 + leases 53.4 − cash 369.9 (Stockopedia: HK$2.51bn)

P/E (trailing, FY2026 EPS 15.10c)

6.4x

Stockopedia forward 12-month: 5.8x

EV / adjusted EBITDA (FY2026)

4.6x

Stockopedia: 4.63x

EV / sales (FY2026)

1.6x—

P/B (attributable equity HK$2,316.0m)

0.84x

Stockopedia: 0.84x

Dividend yield (FY2026 DPS 9.0c)

9.3%

Stockopedia forward: 10.65%

Per-Share Data and Dividends & Capital Returns

MetricFY2022FY2023FY2024FY2025FY2026

Interim DPS (HK cents)

1.202.802.503.504.25

Final DPS (HK cents)

2.682.383.005.504.75

Special DPS (HK cents)

0029.526.000

Total DPS (HK cents)

3.885.1835.0215.009.00

Total dividends for the year (HKD Mn)

———299.8180.0

Capital Markets

ItemStatus

Buyback authorisation

General mandate to repurchase up to 10% of issued shares (excluding treasury shares), renewed at the 11 Aug 2026 AGM; no executed buybacks identified

Issuance mandate

Up to 20% of issued shares

Credit ratings (Moody's / S&P / Fitch)

Not rated (none publicly disclosed)

Debt maturity at 31 Mar 2026

HK$478.0m due within one year; HK$379.5m due after one year (detailed ladder not captured); all in HK$; unsecured

Lease liabilities

HK$26.5m current; HK$26.9m non-current

Analyst Conclusions

Management guidance

No numerical guidance. Management is "optimistic" about the outlook. It cites demographics, chronic disease, primary-care reform (CPP from Q4 2026), patent expiries, the faster drug-approval pathway and GBA integration. It plans to keep pursuing in-licensing, focused R&D in chronic and specialty therapies, manufacturing upgrades (Tai Po first-line trial production by H1 2027), public tenders and community pharmacy initiatives.

Consensus expectations

Consensus revenue and EPS forecasts were not captured. Stockopedia's 12-month rolling forward P/E of 5.8x (versus 6.4x trailing) implies modest expected earnings growth of roughly 10%. That is an inference from the multiples, not a published consensus figure.

Bull case

  1. Defensive cash machine priced like a value trap. HK$301.6m of attributable profit, a 34.5% adjusted EBITDA margin and ROE of about 12.5% are valued at 6.4x P/E, 4.6x EV/EBITDA and 0.84x book, with a 9.3% yield. Even no growth supports a re-rating.

  2. Specialty mix shift. 46 in-licences in FY2026, a 241-product pipeline, biosimilars and the CAR-T niche can lift growth back to the 7% continuing-revenue CAGR of FY2023–FY2026 once the flu effect has passed.

  3. Policy tailwinds and capacity. CPP, CDF and CDCC broaden private and community demand just as the Tai Po plant (10 smart lines) arrives in 2027–2029, adding capacity and potentially exports.

Bear case

  1. Growth has stalled and leverage is rising. Revenue −0.5%, profit from operations −6.2% and adjusted EBITDA −5.4% in FY2026, while net gearing rose to 20.8% before a HK$607.2m capex programme that will not earn revenue until FY2028 or later.

  2. Concentration risk. About 51% of revenue comes from one public buyer and about 97% from Hong Kong. Any Hospital Authority procurement or pricing reform hits earnings directly.

  3. Governance discount persists. A founder-controlled board (70.25% stake), a combined Chair/CEO, recurring connected transactions with JBM, INED turnover, and a 25-point drop in CGU impairment headroom all justify a structural discount.

Catalysts and monitorables (next 12 months)

Expected timingCatalyst / monitorable
Late Nov 2026H1 FY2027 interim results: watch revenue trend against the normalised H1 FY2026 base, gross margin, and the interim DPS (4.25c last year)
Q4 2026 onwardCommunity Pharmacy Programme rollout and Jacobson's role in it
Winter 2026/27Severity of the influenza season (cold and flu sales)
H1 2027Tai Po first-line trial production; capex spend against the HK$607.2m contract
OngoingNew in-licensing deals, biosimilar launches, CAR-T case volume (4 to date)
OngoingNet gearing path; refinancing of HK$478m in current bank loans
OngoingBoard independence after the Aug 2026 INED change; connected transactions with JBM
Jun 2027FY2027 results and dividend decision (any special dividend?)
OngoingAny use of the 10% buyback mandate at sub-book valuations

Analyst verdict

Jacobson Pharma has finished turning itself from a mixed generics and consumer-brands group into a focused Hong Kong essential-medicines franchise, and the financial results back up that choice. On a continuing basis, revenue grew at about 7% a year from FY2023 to FY2026. Gross margin widened to about 43%, attributable profit rose to a record HK$301.6m, and ROE roughly doubled from pre-separation levels. Its competitive position rests on being the largest local generic supplier, owning nine GMP facilities, holding a large registration book and pipeline, and controlling distribution into almost every public and private prescriber. That position is hard to copy in a small market that multinationals mostly ignore.

The market's de-rating, about 33% over a year to roughly 6x earnings and below book value, reflects three real concerns rather than mispricing alone. First, FY2026 showed that underlying growth is fragile without help from a strong flu season. Second, the company is entering a capex-heavy phase (HK$607m-plus at Tai Po) funded by more short-term bank debt, with returns that will not arrive until 2027–2029. Third, governance remains founder-centric, with recurring related-party dealings involving JBM.

We would describe the equity as a high-yield, low-multiple defensive holding with execution-dependent upside. At HK$0.97, the about 9% cash yield and about 15% earnings yield provide meaningful downside support, as long as Hospital Authority pricing stays rational and leverage stays below roughly 1.5x EBITDA. A re-rating needs evidence that the specialty and in-licensing engine can deliver mid-single-digit organic growth in a normal flu year, starting with the November 2026 interim results, and that Tai Po stays on budget. Investors should also watch for any narrowing of the governance discount, for example through buyback use, splitting the Chair and CEO roles, or fewer connected transactions. Without these, the stock may stay a cheap income vehicle rather than a compounding story.


Dossier compiled from public filings and market data accessible as of 11 October 2026. no figures have been estimated except where explicitly labelled "(computed)" or "inference".

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleBoard tenureCommitteesBackground (as disclosed)Age

Mr. Sum Kwong Yip, Derek

Chairman and CEO; Executive Director; founder

Since establishment

Executive Committee (Chair)

Founder; has managed the group's business and strategic planning since establishment; controlling shareholder of both Jacobson and JBM Healthcare

Not captured

Mr. Yim Chun Leung

Executive Director; authorised representative

Not captured

Executive, ESG (left Nomination 28 Jul 2025)

Brother-in-law of former INED Prof. Lam Sing Kwong, Simon

Not captured

Ms. Pun Yue Wai

Executive Director; authorised representative

Not captured

Executive, Remuneration, Nomination (from 28 Jul 2025)

Only female director

Not captured

Prof. Wong Chi Kei, Ian

Non-executive Director

Not captured

—

Academic (details not captured)

Not captured

Dr. Lam Kwing Tong, Alan

INED; served more than 9 years

Since 30 Aug 2016

Remuneration (Chair since 21 Sep 2016), Audit, Nomination

Private dental practice; BDS (Glasgow, 1987); MGDS RCS Edinburgh (1999); Hong Kong Dental Academy membership (2013); fee HK$230,000 a year; deemed interest in 600,000 shares

63

Mr. Luk Ting Lung, Alan

INED

Since 28 Jul 2025

ESG Committee (Chair), Audit; also chairs Risk Management Committee per AGM circular

39+ years in financial services: MD of Hobbit Family Office; CEO of Hobbit Asset Management; Hang Seng Bank Head of Private Banking and Trust (2010–2021); American Express Bank (1999–2008, incl. Alternate CEO); Schroders; HSBC Investment Bank. MBA (Murdoch), MSc Global Finance (HKUST/NYU Stern). Also INED of JBM (Healthcare) (2161) since Jan 2021. Fee HK$230,000 a year.

64

Mr. Young Chun Man, Kenneth

INED (former)

Until 11 Aug 2026

Former Audit and Nomination Chair; Remuneration member

Accounting and finance expert (Listing Rule 3.10(2)); retired citing other business commitments

Not captured

Prof. Lam Sing Kwong, Simon

INED (former)

Retired 28 Jul 2025

Former ESG Chair; Audit member

—

Not captured

New INED (appointed at or after the 11 Aug 2026 AGM)

INED

From Aug 2026

Committee changes announced

——

Directors' Remuneration

Emolument band (HKD)Number of directors

Nil – 1,000,000

5

3,000,001 – 4,000,000

1

7,000,001 – 8,000,000

1

19,000,001 – 20,000,000

1

Major Shareholders

HolderShares (long)% of issued sharesDate of notice

Mr. Sum Kwong Yip, Derek (personal, corporate and deemed interests)

1,405,238,00070.25

22 Jan 2026

Queenshill Development Limited

508,404,00025.42

3 Apr 2025

Mr. Yim Chun Leung (ED)

46,820,0002.34

22 Jan 2026

Ms. Pun Yue Wai (ED)

10,810,0000.54

22 Jan 2026

Dr. Lam Kwing Tong, Alan (INED)

600,000 (deemed)

0.03

AGM circular, Jul 2026

Board & Management Changes

DateChangeContext

28 Jul 2025

Prof. Lam Sing Kwong, Simon retired as INED; Mr. Luk Ting Lung, Alan appointed INED, Audit member and ESG Chair; Mr. Yim left Nomination Committee; Ms. Pun joined

Board refresh; nomination terms of reference revised

23 Jun 2026

Mr. Young Chun Man, Kenneth announced he would not seek re-election

Other business commitments; no disagreement with the board

11 Aug 2026

Mr. Young retired; INED appointment and committee changes announced

—

Competitive Landscape

Key Competitors

CompetitorTypeOverlap with JacobsonRevenue (latest disclosed)Relative positioning

Hospital Authority multi-source tenders (all bidders)

Market structure

Public generic tenders

—

One buyer sets prices; Jacobson is the largest local supplier

Sandoz (global generics)

Multinational generics

HK generic registrations and tenders

Global; HK not disclosed

Global scale; selective HK portfolio

Teva Pharmaceutical

Multinational generics

HK generics

Global; HK not disclosed

Selective HK presence

Viatris

Multinational generics and brands

HK chronic-disease generics

Global; HK not disclosed

Branded-generic focus

Local HK manufacturers (e.g., Vickmans Laboratories, Universal Pharmaceutical Laboratories)

Private local generic makers

HK public and private generics

Not publicly disclosed (private)

Smaller; Jacobson's share was more than the next two combined (2016)

JBM (Healthcare) Ltd (2161.HK)

Former subsidiary; consumer health and proprietary Chinese medicine

Limited (OTC and pharmacy channel)

HK$834.6m (FY Mar 2026); +6.7%

Same controlling shareholder; complementary more than competing

Lee's Pharmaceutical (0950.HK)

HK-listed specialty and in-licensing pharma

In-licensed specialty drugs, HK/China

HK$1,436m (FY Dec 2025); +2.6%

Stronger China and R&D presence; lower margins

China Medical System (0867.HK)

Specialty in-licensing and commercialisation

Specialty in-licensing model (mainly Mainland)

RMB8,212m (FY Dec 2025); +10.0%

Much larger; Mainland-focused

Zuellig Pharma; DKSH

Distributors / logistics

Pharmaceutical logistics, cold chain, in-licensed distribution

Not disclosed for HK

Compete for principals' distribution mandates

Other licensed CAR-T / ATP handler (one other in HK)

Logistics

ATP handling

—

Duopoly in HK CAR-T handling

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricJacobson (FY Mar 2026)JBM Healthcare (FY Mar 2026)Lee's Pharm (FY Dec 2025)China Medical System (FY Dec 2025)

Revenue

HK$1,569.5m

HK$834.6m

HK$1,436m

RMB8,212m

Revenue growth

−0.5%+6.7%+2.6%+10.0%

Gross margin

43.2%55.8%50.8%71.5%

Operating margin

24.8% (company) / 24.7% (S&P)

31.6%7.7%19.2%

Net margin

19.2%24.1%6.4%18.1%

R&D intensity (expensed)

≈0.0% (most development capitalised)

—

7.7% (HK$111.0m)

7.1% (RMB585.0m)

“—” = not publicly disclosed.

Recent Developments

All of them are listed below, with immediately preceding context items flagged.

Company Snapshot

$201.5M

Revenue

1,768

Employees

$250M

Market Cap

Cayman Islands

Headquarters

SWOT Analysis

Strengths

  • Margin leadership among HK-listed pharma peers: FY2026 gross margin 43.2% and adjusted EBITDA margin 34.5% (AR FY2026), against a 7.7% operating margin at Lee's Pharm (FY2025).
  • Earnings resilience: Attributable profit rose for the fourth straight year to HK$301.6m in FY2026, even with a 0.5% revenue dip (FY2022 HK$177.7m → FY2026 HK$301.6m).
  • Scale and supply security: Nine licensed HK production facilities; eye-drop output +7.8%, oral-liquid +65.5%, semi-solid ×4.7 in FY2026 (AR FY2026).
  • Deep pipeline: 241 products, 23 approvals in FY2026, and 10 pending registration (AR FY2026).
  • Licensing platform: 46 in-licensing agreements in FY2026, more than double the 20 in FY2025 (AR FY2025, AR FY2026).
  • Niche in advanced therapy logistics: One of two authorised CAR-T handlers in HK; Yikaida rolled out in HK and Macau (AR FY2026).
  • Conservative finances: Net debt/EBITDA about 0.9x; interest cover 12.7x; no pledged assets (AR FY2026; computed).

Weaknesses

  • Customer concentration: One customer contributed HK$800.8m (about 51%) of FY2026 revenue (FY2026 results, segment note).
  • Geographic concentration: Hong Kong is 96.5% of FY2026 revenue; Mainland revenue fell 32.7% (AR FY2026).
  • Seasonality: H1 FY2026 revenue −5.4% and FY2026 adjusted EBITDA −5.4% because of normalised flu (interim results; AR FY2026).
  • Low disclosed R&D: Expensed R&D of HK$0.1m in FY2026; total R&D investment not disclosed (FY2026 results).
  • Working-capital intensity: Inventory about 152 days of COGS; cash conversion cycle about 172 days (computed from FY2026 balance sheet).
  • Governance concentration: Combined Chair/CEO (CG Code C.2.1 deviation); founder holds 70.25%; outsourced internal audit (AR FY2026; etnet).
  • Shrinking impairment headroom: CGU headroom fell to HK$825.8m from HK$1,268.3m in one year (AR FY2026).

Opportunities

  • Primary-care reform: The CPP rolls out from Q4 2026 alongside CDF and CDCC, which should lift private and community demand for cost-effective generics (AR FY2026).
  • Biosimilars and biologics: Expansion of prefilled syringe and pen formats as biologic patents expire (AR FY2026).
  • Tai Po smart factory: Ten lines with AI and robotics from H1 2027 to H1 2029 could lower unit costs and support export ambitions (AR FY2026).
  • Faster drug registration: The primary evaluation mechanism from March 2026 could speed up in-licensed launches (AR FY2026).
  • GBA access: Arsenic Trioxide Oral Solution is already approved for GBA designated hospitals; further products could follow (FY2023 interim).
  • Adjacent markets: Veterinary (animal-cancer DNA test) and vaccines (influenza range) entered in FY2026 (AR FY2026).
  • Capital return capacity: About 9.3% dividend yield at HK$0.97, plus a renewed 10% buyback mandate (AGM circular 2026; computed).

Threats

  • Tender price compression from a single dominant public buyer (structural; inferred from the 51% concentration).
  • Capex execution risk: HK$607.2m contract; schedule slipped from end-2026/2028 to H1 2027/2029; stated size changed between reports (AR FY2025 vs AR FY2026).
  • Rising leverage and short-dated debt: Current bank loans HK$478.0m vs HK$237.2m; net gearing 20.8% (FY2026 results).
  • Mainland weakness (Mainland revenue −32.7%) and wider geopolitical uncertainty (AR FY2026).
  • Market de-rating: Share price fell from HK$1.78 (Jul 2025) to HK$0.97 (Oct 2026); analyst average target cut 16% (AGM circular; Simply Wall St).
  • Related-party perception: Repeated connected transactions with the Sum-controlled JBM group (Nov 2024, Oct 2025, Mar 2026, Jun 2026) (HKEX).
  • Product liability and quality risk: The company says its product liability insurance may not cover all claims (AR FY2026 risk section).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Feb–Mar 2025 (context)Tai Po facility won by tender; Yikaida launched 20 Feb 2025; first HK reinfusion 20 Mar 2025; additional Europharm–LCSTH licence 28 Feb 2025Sets up the capex and advanced-therapy themes
13 Jun 2025FY2025 results: revenue HK$1,576.9m (+7.4%); attributable profit HK$300.8m (+12.7%); adjusted EBITDA HK$572.8m (+26.4%); final DPS 5.5c plus special 6.0cRecord earnings, helped by a long flu season
13 Jun 2025Announcement that INED Prof. Lam Sing Kwong would retireBoard refresh
3 Jul 20252024/2025 Annual Report published—
Jul 2025Share price peaks at HK$1.78 (12-month high per AGM circular)Valuation high point
28 Jul 20252025 AGM; Mr. Luk Ting Lung appointed INED; committee reshuffle; Nomination Committee terms revisedGovernance
H1 FY2026Flu season ends early; cold and flu demand fallsRevenue headwind
28 Oct 2025Factory licence agreement with JBM's Europharm HK (HK$247k a month to Jan 2028)Connected transaction; small rental income
18 Nov 2025H1 FY2026 results: revenue HK$766.6m (−5.4%); profit from operations HK$183.4m (−6.3%); attributable profit HK$142.0m (+1.2%); interim DPS raised to 4.25c (+21.4%)First sign of top-line pressure; dividend confidence
Nov–Dec 2025Share price falls from about HK$1.49 to about HK$1.22De-rating after the interim results
12 Dec 20252025/2026 Interim Report published—
22 Jan 2026Directors' interest notices: Mr. Sum 70.25%; Mr. Yim 2.34%; Ms. Pun 0.54%Shows control; share-award related changes (inference)
6 Mar 2026Renewal of continuing connected transactions with the JBM groupRelated-party framework continues
Mar 2026HK primary evaluation mechanism for new drug registration begins (phased)Faster approvals for novel products
By Mar 2026Yikaida: 3 HK and 1 Macau patients complete apheresis and reinfusion; first Macau administrationCAR-T commercial traction
FY2026 (year to Mar 2026)46 in-licensing agreements; 23 new product approvals; influenza vaccines and animal-cancer DNA test addedPortfolio expansion
FY2026Bank loans up HK$143.8m to HK$857.5m; net gearing 8.3% → 20.8%Re-leveraging for capex
1 Apr 2026HK$607.2m Tai Po infrastructure and specialised facility works contract accepted (discloseable transaction)Largest capex commitment in the period
Apr–Jun 2026Share price slides to HK$0.98 (June low)1-year total shareholder return about −33%
5 Jun 2026Board meeting date notice—
23 Jun 2026FY2026 results: revenue HK$1,569.5m (−0.5%); attributable profit HK$301.6m (+0.3%); adjusted EBITDA −5.4%; final DPS 4.75c (total 9.0c, no special)Flat year; lower total payout
23 Jun 2026INED Mr. Young Chun Man, Kenneth to retire at the 2026 AGMLoss of the audit-committee chair
29 Jun 2026Joint announcement with JBM: connected transaction in Li Chung Shing Tong sharesRelated-party dealing
16 Jul 20262025/2026 Annual Report, ESG Report, AGM circular (general mandates to buy back 10% and issue 20%)Annual disclosure cycle
11 Aug 2026AGM: all resolutions including final dividend; INED appointment and committee changes; Mr. Young retiresGovernance continuity
Aug–Sep 2026Analyst average price target cut 16% to HK$2.06 (2 analysts)Sell-side caution
9–10 Sep 2026Register closed for final dividend—
5 Oct 2026FY2026 final dividend of 4.75c paidCash return about HK$95m
9–10 Oct 2026Shares at HK$0.97, near the 52-week low of HK$0.94Trailing P/E about 6.4x; yield about 9.3%
Q4 2026 (upcoming)Community Pharmacy Programme phased rolloutPossible new private-channel volume
Late Nov 2026 (expected)H1 FY2027 interim results (based on past timing)Next catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit (FY2022–FY2026): Revenue fell from HKD 1,595.5 Mn in FY2022 to HKD 1,569.5 Mn in FY2026.
Jacobson Pharma Corporation Limited — Income Statement: Revenue & Gross Profit (FY2022–FY2026)
Series (HKD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue1,595.51,785.61,467.81,576.91,569.5
Revenue, continuing-ops basis1,191.31,267.61,467.81,576.91,569.5
Cost of sales9751,038.4847.3884891.6
Gross profit620.5747.2620.5692.9677.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. [Jacobson Pharma 2025/2026 Annual Report (HKEX, 16 Jul 2026)]( (www1.hkexnews.hk)
  2. [FY2026 Annual Results Announcement (HKEX, 23 Jun 2026)]( (www1.hkexnews.hk)
  3. [INED retirement announcement (HKEX, 23 Jun 2026)]( (www1.hkexnews.hk)
  4. [2024/2025 Annual Report (HKEX, 3 Jul 2025)]( (hkexnews.hk)
  5. [FY2024 Annual Results Announcement (HKEX, 20 Jun 2024)]( (www1.hkexnews.hk)
  6. [FY2023 Annual Results Announcement (HKEX, 15 Jun 2023)]( (www1.hkexnews.hk)
  7. [FY2022 Annual Report (HKEX, 27 Jul 2022)]( (www1.hkexnews.hk)
  8. [2026 AGM Circular (17 Jul 2026)]( (pdf.dfcfw.com)
  9. [2026 AGM Notice]( (pdf.dfcfw.com)
  10. [2026 AGM Proxy Form]( (pdf.dfcfw.com)
  11. [etnet – HKEX announcements index, 2633]( (etnet.com.hk)
  12. [etnet – Disclosure of interests, 2633]( (etnet.com.hk)
  13. [etnet – Stock news, 2633]( (etnet.com.hk)
  14. [ACN Newswire – FY2026 Annual Results release]( (acnnewswire.com)
  15. [ACN Newswire – FY2025 Annual Results release]( (acnnewswire.com)
  16. [Quamnet – FY2025 results release]( (quamnet.com)
  17. [ACN Newswire – FY2023 Interim Results release]( (acnnewswire.com)
  18. [iTiger – H1 FY2026 interim results]( (itiger.com)
  19. [iTiger – Tai Po contractor appointment]( (itiger.com)
  20. [iTiger – 2025 Europharm licence agreement]( (itiger.com)
  21. [iTiger – FY2026 annual profit report]( (itiger.com)
  22. [FilingReader – FY2026 results summary]( (filingreader.com)
  23. [FinancialFilings – Jacobson Pharma filings]( (financialfilings.com)
  24. [TipRanks – Li Chung Shing Tong share transaction]( (tipranks.com)
  25. [ACN Newswire – IPO details (Sep 2016)]( (acnnewswire.com)
  26. [ACN Newswire – Medipharma acquisition (Oct 2016)]( (acnnewswire.com)
  27. [ACN Newswire – Ho Chai Kung acquisition (Dec 2016)]( (acnnewswire.com)
  28. [ACN Newswire – Hong Ning Hong acquisition (Mar 2017)]( (acnnewswire.com)
  29. [ACN Newswire – JBM spin-off Form A1 (Sep 2020)]( (acnnewswire.com)
  30. [ACN Newswire – Jacobson Pharma press release archive]( (acnnewswire.com)
  31. [BrandSpur – JBM distribution in specie (Jan 2021)]( (brandspurng.com)
  32. [BioSpace – HK$500m convertible notes (Oct 2017)]( (biospace.com)
  33. [BioSpace – US$85m IPO]( (biospace.com)
  34. [BioSpace – US$64m raise for M&A]( (biospace.com)
  35. [Stockopedia – 2633 share price]( (stockopedia.com)
  36. [Simply Wall St – Jacobson Pharma]( (simplywall.st)
  37. [StockAnalysis – Jacobson Pharma income statement]( (stockanalysis.com)
  38. [StockAnalysis – JBM Healthcare income statement]( (stockanalysis.com)
  39. [StockAnalysis – Lee's Pharmaceutical income statement]( (stockanalysis.com)
  40. [StockAnalysis – China Medical System income statement]( (stockanalysis.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.